Johnson & Johnson plans to separate orthopaedics unit DePuy Synthes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St indexes fall to two-week lows as rising bond yields, disappointing Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Johnson & Johnson Announces Intent to Separate Its Orthopaedics Business
October 14, 2025 6:21 AM EDTStrengthens focus of Johnson & Johnson as an innovation powerhouse and accelerates the portfolio shift of its MedTech Segment to higher-growth and higher-margin markets
Standalone orthopaedics business would operate as DePuy Synthes and be the largest, most comprehensive orthopaedics-focused company in the world
Namal Nawana appointed to serve as Worldwide President of DePuy Synthes
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (the Company) (NYSE: JNJ) today announced the Companys intent to separate its Orthopaedics business to enhance... More
